Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy—Either, Neither, or Both

Marcel Levi, MD, PhD, FRCP1,2 Jecko Thachil, MD, FRCP3

1 Department of Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom
2 NIHR UCLH/UCL Biomedical Research Centre, London, United Kingdom
3 Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom


Address for correspondence Marcel Levi, MD, Department of Medicine, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London NW1 2PG, United Kingdom (e-mail: marcel.levi@nhs.net).

Patients with severe coronavirus disease 2019 (COVID-19) infections manifest coagulation abnormalities that have been associated with respiratory deterioration and death.1,2 In addition, many patients with severe COVID-19 infections develop venous thromboembolism, which seems to be related to the coagulopathy.3 It has also been suggested that undiagnosed pulmonary embolism contributes to a sudden deterioration of pulmonary oxygen exchange that is sometimes seen in patients with COVID-19 infections.4,5

The coagulopathy associated with COVID-19 mimics other systemic coagulopathies that are regularly seen in severe infections, such as disseminated intravascular coagulation (DIC) or thrombotic microangiopathy (TMA).6–8 However, at the same time, the clinical and laboratory characteristics of the coagulation changes in COVID-19 are distinctly different from the common presentation of these conditions.

Coagulation Tests in COVID-19

The most striking coagulation test abnormality in severe COVID-19 patients is an abnormally high D-dimer level.1,2,9,10 In several series of patients with COVID-19, markedly increased D-dimer levels were observed in almost 50% of patients. Also, patients with D-dimer levels more than sixfold the upper limit of normal were found to have an increased need for mechanical ventilation and a significantly higher risk of death.

Another coagulation abnormality that is seen in the most severe patients is thrombocytopenia.11,12 Most of these patients have a platelet count between 100 and 150 × 10⁹/L, and lower platelet counts are rarely (<5%) seen.9,13 In contrast to thrombocytopenia associated with other infections including viral disease and bacterial sepsis,14 a low platelet count in COVID-19 has not been significantly associated with an adverse outcome, although very low platelet counts can be an exception.11

The prothrombin time in patients with more severe COVID-19 infection is only mildly prolonged (~3 seconds).2,15 Prolongation of the activated partial thromboplastin time (aPTT) is less clear and might be obscured by (very) high levels of factor VIII and fibrinogen that instead sometimes leads to shortening of the aPTT.

Mean fibrinogen plasma concentration in COVID-19 patients are strikingly high, which is likely due to an acute phase response.2 However, a swift drop in plasma fibrinogen to concentrations below <1.0 g/L was demonstrated in a small number of the most severe COVID-19 patients in China, shortly before they died.

Plasma levels of protease inhibitor such as protein C and antithrombin are slightly decreased, in particular in the nonsurviving patients, but plasma concentrations seldom fall below 80% of normal values.2

Is this Disseminated Intravascular Coagulation?

The combination of increased D-dimer, thrombocytopenia, and prolonged global coagulation tests mimics the pattern seen in DIC.9 However, there seem to be distinct differences from DIC commonly seen in patients with sepsis, cancer, or other underlying conditions known to be associated with DIC. First, in most cases with DIC complicating a serious systemic condition, a more profound thrombocytopenia is observed.10 Also, these patients usually have much lower levels of coagulation factors (in particular factors II, V, VII, and X) and severely decreased plasma concentrations of physiological anticoagulants such as antithrombin and protein C.17

1 Department of Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom
2 NIHR UCLH/UCL Biomedical Research Centre, London, United Kingdom
3 Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom

Published online: 2020-06-08
One of the pathogenetic hallmarks of DIC is dysregulated thrombin generation, usually as a result of tissue factor expression on mononuclear and possibly endothelial cells induced by proinflammatory cytokines, most prominently interleukin (IL)-6. While IL-6 and other pro-inflammatory cytokines were shown to be extremely elevated in severe COVID-19 infection, there is not yet definitive proof of excessive thrombin generation in these patients. Observations with a thrombin generation test and assessment of markers for prothrombin to thrombin activation (F1+2) and thrombin-antithrombin complexes would be helpful in obtaining further insight into this issue.

In view of the coagulation test results, most patients with COVID-19 would not reach a score sufficiently high to be diagnosed with overt DIC according to the DIC score of the International Society on Thrombosis and Haemostasis (ISTH). The clinical presentation of the COVID-19 coagulopathy is mostly prothrombotic, with a high incidence of overt venous (and possibly arterial) thromboembolism, and not many hemorrhagic complications, which is no surprise in the absence of a real consumption coagulopathy.

Taken together, it might be fair to conclude that the coagulopathy of COVID-19 should be classified as a specific form of intravascular coagulation, which is distinctly different from DIC commonly seen in other conditions and may need new diagnostic criteria.

Is this Thrombotic Microangiopathy?

TMA is a result of increased platelet adhesion to the vascular endothelium in association with platelet aggregation and activation, causing consumptive thrombocytopenia. The resultant platelet thrombi in the microvasculature cause impaired organ function and classically contribute to complications such as renal insufficiency or neurological disease as well as microangiopathic hemolysis.

Histopathology from postmortem examinations in COVID-19 patients has shown typical microvascular platelet-rich thrombotic depositions in small vessels of the lungs along the foci of local hemorrhage and accumulation and entrapment of inflammatory cells, such as neutrophils, in alveolar capillaries. This picture is compatible with pulmonary TMA. There was not a lot of evidence for microvascular platelet-rich thrombi in other organs.

Overt intravascular hemolysis and severe thrombocytopenia, as seen in typical cases of thrombotic thrombocytopenic purpura (TTP), is not a clinical feature of COVID-19 infection. However, some other laboratory abnormalities in severe COVID-19 that may point to a form of TMA are an increased LDH and, in some patients, strikingly high ferritin levels, in particular in patients with the most severe organ dysfunction.

Pathologically increased platelet–vessel wall interaction as seen in TMA is caused by the presence of ultra-large von Willebrand factor multimers released from injured endothelial cells. Under physiological circumstances, these multimers would be cleaved by ADAMTS-13 (a disintegrin and metalloprotease with a thrombospondin type I motif-13). However, COVID-19 infection with associated endothelial cell perturbation may lead to decreased ADAMTS-13 levels due to consumption or proteolytic degradation, resulting in high levels of uncleaved von Willebrand factor multimers and ensuing deposit of microvascular platelet thrombi. This mechanism has been shown to occur in other severe infectious conditions. Currently, there are no data on ADAMTS-13 levels in severe COVID-19 infection.

Taken together, there is evidence of a localized TMA as evidenced by microvascular thrombosis in COVID-19-affected lungs, but there is no strong evidence for a systemic TMA.

Pathogenetic Pathways Specific for COVID-19 Coagulopathy

Coronavirus infections seem to be associated with a typical activation of the fibrinolytic system. Experiments in mice with a targeted deletion of urokinase-type plasminogen activator indicated that the urokinase-driven pathway was an important mediator of lethality. Moreover, patients with human SARS-CoV-1 infection had sixfold increased plasma levels of t-PA (tissue-type plasminogen activator). Presumably, the COVID-19 inflammation-induced endothelial cell injury may cause a massive release of plasminogen activators. The resulting plasmin generation may be an important factor explaining the high levels of D-dimer seen in patients with severe COVID-19 infection. In addition, plasmin-mediated effects on the metalloproteinase system may result in changes in the extracellular matrix, facilitating capillary leakage and pulmonary edema.

There is a strong connection between bronchoalveolar coagulation and fibrinolysis and the pathogenesis of acute respiratory distress syndrome (ARDS), in which enhanced intrapulmonary fibrin deposition due to abnormal bronchoalveolar fibrin turnover is a crucial factor. Measurement of coagulation and fibrinolysis factors in the bronchoalveolar fluid have demonstrated that enhanced intrapulmonary thrombin generation, insuffiently balanced by physiological anticoagulant factors and endogenous fibrinolysis, is mediating this pathogenetic pathway. The clinical and laboratory picture of serious ARDS in ventilated COVID-19 patients and important coagulopathic changes point to an important role of bronchoalveolar and pulmonary vascular fibrin turnover in the most severe patients.

Conclusion

Severe COVID-19 infection is associated with coagulation abnormalities that encompass elements reminiscent of both DIC and TMA. However, this coronavirus infection seems to cause a specific coagulopathy that is more localized and distinctly different from “classical” DIC or TMA syndromes. The specific coagulopathic features of this disease are likely relevant in view of the high incidence of thromboembolic complications in severely affected patients and may present an important point of impact for (supportive) preventive or therapeutic management strategies to improve the clinical outcome.
Conflicts in Interest
None.

References


